NasdaqGM:RYTMBiotechs
Rhythm Algorithm Aims To Clarify Bardet Biedl Diagnosis And Market Potential
Rhythm Pharmaceuticals (NasdaqGM:RYTM) has published a new evidence-based diagnostic algorithm for Bardet-Biedl syndrome.
The algorithm is designed to streamline and accelerate clinical diagnosis of this rare obesity disorder.
The update incorporates recent advances in genetic testing to support earlier and more accurate identification of BBS.
Rhythm Pharmaceuticals focuses on treatments for rare genetic forms of obesity, and Bardet-Biedl syndrome is a core part of that remit. A clearer...